Positron emission tomography and circulating tumor cells to monitor a dramatic response to gefitinib.
Medical Oncology Unit, Thoraco-Pulmonary Department, National Cancer Institute, Napoli, Italy. alessandromorabito1@virgilio.it
Alessandro
A
Morabito
Claudia
C
Sandomenico
Raffaele
R
Costanzo
Agnese
A
Montanino
Corradina
C
Caraco
Elisabetta
E
De Lutio
Simona
S
Bevilacqua
Raffaella
R
Pasquale
Antonietta
A
Caronna
Gerardo
G
Botti
Nicola
N
Normanno
Gaetano
G
Rocco
D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics / Q000556:secondary*; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D008297:Male; D009154:Mutation / Q000235:genetics; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D049268:Positron-Emission Tomography; D011379:Prognosis; D011799:Quinazolines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011799:Quinazolines; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077156:Gefitinib